Type 2 diabetes mellitus
Conditions
Interventions
Undergoing DPP-4 inhibiter, such as alogliptin 12.5mg , Vildagliptin 100mg, Sitagliptin 50mg etc for over 12 weeks, patients are treated with omega 3 fatty acid 1800mg for 16 weeks.
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetes with dsylipidemia 2) Pts with written IC 3)Age more than 20, less than 85 4) HbA1c :more than 7.0% 5)before test registration –alogliptin 12.5mg, vildagliptin 100mg,sitagliptin 50mg, or linagliptin 5mg for at least 12 weeks and outpatient
Exclusion criteria
Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)present or history of CHF 3)severe infection, before operation, severe trauma 4)severe hepatic dysfunction 5)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 6)pregnacy 7)Allergy for DPP-4 inhibitores or omega 3 fatty acid 8)Patients judged by the investigator to be ineligible for some other reason 9)Changes of doses with oral hypoglycemic agents or antihyperelipidemic drugs during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate of postprandial glucose and HbA1c after add-on therapy with omega 3-fatty acid | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Lipid parameters(TC,LDL-C, HDL-C, TG,etc) 2)Renal function (ACR, Cr, eGFR) | — |
Countries
Japan
Contacts
Public ContactJun Suzuki
Yokohama City University Medical Center Department of Endocrinology and Diabetes
Outcome results
None listed